Top

Published in:

Open Access 01-11-2018 | Original Paper

Improved recovery from limb ischaemia by delivery of an affinity-isolated heparan sulphate

Authors: Selina Poon, Xiaohua Lu, Raymond A. A. Smith, Pei Ho, Kishore Bhakoo, Victor Nurcombe, Simon M. Cool

Published in: Angiogenesis | Issue 4/2018

Abstract

Peripheral arterial disease is a major cause of limb loss and its prevalence is increasing worldwide. As most standard-of-care therapies yield only unsatisfactory outcomes, more options are needed. Recent cell- and molecular-based therapies that have aimed to modulate vascular endothelial growth factor-165 (VEGF₁₆₅) levels have not yet been approved for clinical use due to their uncertain side effects. We have previously reported a heparan sulphate (termed HS7) tuned to avidly bind VEGF₁₆₅. Here, we investigated the ability of HS7 to promote vascular recovery in a murine hindlimb vascular ischaemia model. HS7 stabilised VEGF₁₆₅ against thermal and enzyme degradation in vitro, and isolated VEGF₁₆₅ from serum via affinity-chromatography. C57BL6 mice subjected to unilateral hindlimb ischaemia injury received daily intramuscular injections of respective treatments (n = 8) and were assessed over 3 weeks by laser Doppler perfusion, magnetic resonance angiography, histology and the regain of function. Mice receiving HS7 showed improved blood reperfusion in the footpad by day 7. In addition, they recovered hindlimb blood volume two- to fourfold faster compared to the saline group; the greatest rate of recovery was observed in the first week. Notably, 17% of HS7-treated animals recovered full hindlimb function by day 7, a number that grew to 58% and 100% by days 14 and 21, respectively. This was in contrast to only 38% in the control animals. These results highlight the potential of purified glycosaminoglycan fractions for clinical use following vascular insult, and confirm the importance of harnessing the activity of endogenous pro-healing factors generated at injury sites.

Available only for authorised users

Fowkes FG, Rudan D, Rudan I et al (2013) Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382:1329–1340. https://doi.org/10.1016/S0140-6736(13)61249-0 CrossRefPubMed

DeRubertis BG, Faries PL, McKinsey JF et al (2007) Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions. Ann Surg 246:414–415. https://doi.org/10.1097/SLA.0b013e31814699a2 CrossRef

Cooke JP, Losordo DW (2015) Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res 116:1561–1578. https://doi.org/10.1161/CIRCRESAHA.115.303565 CrossRefPubMedPubMedCentral

Godman CA, Chheda KP, Hightower LE et al (2010) Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. Cell Stress Chaperones 15:431–442CrossRefPubMed

Fadini GP, Agostini C, Avogaro A (2010) Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 209:10–17. https://doi.org/10.1016/j.atherosclerosis.2009.08.033 CrossRefPubMed

Marui A, Tabata Y, Kojima S et al (2007) A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. Circ J 71:1181–1186CrossRefPubMed

de Souza Lins Borba FK, Felix GLQ, Costa EVL et al (2016) Fractal analysis of extra-embryonic vessels of chick embryos under the effect of glucosamine and chondroitin sulfates. Microvasc Res 105:114–118. https://doi.org/10.1016/j.mvr.2016.02.005 CrossRefPubMed

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676. https://doi.org/10.1038/nm0603-669 CrossRefPubMed

Couffinhal T, Silver M, Zheng LP et al (1998) Mouse model of angiogenesis. Am J Pathol 152:1667–1679PubMedPubMedCentral

10.

Takeshita S, Zheng LP, Brogi E et al (1994) Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93:662–670. https://doi.org/10.1172/JCI117018 CrossRefPubMedPubMedCentral

11.

Rajagopalan S, Mohler ER 3rd, Lederman RJ et al (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent cl. Circulation 108:1933–1938. https://doi.org/10.1161/01.CIR.0000093398.16124.29 CrossRefPubMed

12.

Eppler SM, Combs DL, Henry TD et al (2002) A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72:20–32. https://doi.org/10.1067/mcp.2002.126179 CrossRefPubMed

13.

Manning MC, Patel K, Borchardt RT (1989) Stability of protein pharmaceuticals. Pharm Res 6:903–918CrossRefPubMed

14.

Kaminski KA, Bonda TA, Korecki J, Musial WJ (2002) Oxidative stress and neutrophil activation—the two keystones of ischemia/reperfusion injury. Int J Cardiol 86:41–59CrossRefPubMed

15.

Carragee EJ, Ghanayem AJ, Weiner BK et al (2011) A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors. Spine J 11:463–468. https://doi.org/10.1016/j.spinee.2011.06.001 CrossRefPubMed

16.

van Wijk XM, van Kuppevelt TH (2014) Heparan sulfate in angiogenesis: a target for therapy. Angiogenesis 17:443–462. https://doi.org/10.1007/s10456-013-9401-6 CrossRefPubMed

17.

Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G (1992) The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 267:6093–6098PubMed

18.

Wang C, Poon S, Murali S et al (2014) Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy. Biomaterials 35:6776–6786. https://doi.org/10.1016/j.biomaterials.2014.04.084 CrossRefPubMed

19.

Brandner B, Kurkela R, Vihko P, Kungl AJ (2006) Investigating the effect of VEGF glycosylation on glycosaminoglycan binding and protein unfolding. Biochem Biophys Res Commun 340:836–839. https://doi.org/10.1016/j.bbrc.2005.12.079 CrossRefPubMed

20.

Blocki A, Wang Y, Koch M et al (2015) Sourcing of an alternative pericyte-like cell type from peripheral blood in clinically relevant numbers for therapeutic angiogenic applications. Mol Ther 23:510–522. https://doi.org/10.1038/mt.2014.232 CrossRefPubMedPubMedCentral

21.

Folker ES, Baylies MK (2013) Nuclear positioning in muscle development and disease. Front Physiol 4:363. https://doi.org/10.3389/fphys.2013.00363 CrossRefPubMedPubMedCentral

22.

Didiasova M, Wujak L, Wygrecka M, Zakrzewicz D (2014) From plasminogen to plasmin: role of plasminogen receptors in human cancer. Int J Mol Sci 15:21229–21252. https://doi.org/10.3390/ijms151121229 CrossRefPubMedPubMedCentral

23.

Lauer G, Sollberg S, Cole M et al (2002) Generation of a novel proteolysis resistant vascular endothelial growth factor165 variant by a site-directed mutation at the plasmin sensitive cleavage site. FEBS Lett 531:309–313CrossRefPubMed

24.

Aitsebaomo J, Srivastava S, Zhang H et al (2011) Recombinant human interleukin-11 treatment enhances collateral vessel growth after femoral artery ligation. Arter Thromb Vasc Biol 31:306–312. https://doi.org/10.1161/ATVBAHA.110.216986 CrossRef

25.

McDermott MM, Hoff F, Ferrucci L et al (2007) Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. J Am Geriatr Soc 55:400–406. https://doi.org/10.1111/j.1532-5415.2007.01092.x CrossRefPubMedPubMedCentral

26.

Gospodarowicz D, Cheng J (1986) Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128:475–484. https://doi.org/10.1002/jcp.1041280317 CrossRefPubMed

27.

Sarrazin S, Lamanna WC, Esko JD (2011) Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3:a004952. https://doi.org/10.1101/cshperspect.a004952 CrossRefPubMedPubMedCentral

28.

Hirsh J, Anand SS, Halperin JL, Fuster V (2001) Guide to anticoagulant therapy: heparin. Circulation 103:2994–3018CrossRefPubMed

29.

Cossette B, Pelletier ME, Carrier N et al (2010) Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative. Ann Pharmacother 44:994–1002. https://doi.org/10.1345/aph.1M615 CrossRefPubMed

30.

Blas J-VV, Carsten CG, Gray BH (2016) Heparin-induced thrombocytopenia associated with a heparin-bonded stent graft. Ann Vasc Surg 33:227.e1–227.e4. https://doi.org/10.1016/j.avsg.2015.11.015 CrossRef

31.

Oh CW, Hoover-Plow J, Plow EF (2003) The role of plasminogen in angiogenesis in vivo. J Thromb Haemost 1:1683–1687. https://doi.org/10.1046/j.1538-7836.2003.00182.x CrossRefPubMed

32.

Keyt BA, Berleau LT, Nguyen HV et al (1996) The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271:7788–7795CrossRefPubMed

33.

Roth D, Piekarek M, Paulsson M et al (2006) Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am J Pathol 168:670–684. https://doi.org/10.2353/ajpath.2006.050372 CrossRefPubMedPubMedCentral

34.

Brenes RA, Jadlowiec CC, Bear M et al (2012) Toward a mouse model of hind limb ischemia to test therapeutic angiogenesis. J Vasc Surg 56:1669–1679. https://doi.org/10.1016/j.jvs.2012.04.067 (discussion 1679).CrossRefPubMedPubMedCentral

35.

Scholz D, Ziegelhoeffer T, Helisch A et al (2002) Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 34:775–787CrossRefPubMed

36.

Brennan TV, Lin L, Huang X et al (2012) Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood 120:2899–2908. https://doi.org/10.1182/blood-2011-07-368720 CrossRefPubMedPubMedCentral

37.

Fang W, Bi D, Zheng R et al (2017) Identification and activation of TLR4-mediated signalling pathways by alginate-derived guluronate oligosaccharide in RAW264.7 macrophages. Sci Rep 7:1663. https://doi.org/10.1038/s41598-017-01868-0 CrossRefPubMedPubMedCentral

38.

Barani J, Nilsson J-Å, Mattiasson I et al (2005) Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 42:75–80. https://doi.org/10.1016/j.jvs.2005.03.025 CrossRefPubMed

39.

Nakamura S, Takikawa M, Ishihara M et al (2012) Delivery system for autologous growth factors fabricated with low-molecular-weight heparin and protamine to attenuate ischemic hind-limb loss in a mouse model. J Artif Organs 15:375–385. https://doi.org/10.1007/s10047-012-0658-0 CrossRefPubMed

40.

Beegle JR, Magner NL, Kalomoiris S et al (2016) Preclinical evaluation of mesenchymal stem cells overexpressing VEGF to treat critical limb ischemia. Mol Ther Methods Clin Dev 3:16053. https://doi.org/10.1038/mtm.2016.53 CrossRefPubMedPubMedCentral

41.

Zhang JC, Zheng GF, Wu L et al (2014) Bone marrow mesenchymal stem cells overexpressing human basic fibroblast growth factor increase vasculogenesis in ischemic rats. Braz J Med Biol Res 47:886–894CrossRefPubMedPubMedCentral

42.

Tong M, Tuk B, Hekking IM et al (2009) Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120. Wound Repair Regen 17:840–852. https://doi.org/10.1111/j.1524-475X.2009.00548.x CrossRefPubMed

43.

Tong M, Tuk B, Hekking IM et al (2011) Heparan sulfate glycosaminoglycan mimetic improves pressure ulcer healing in a rat model of cutaneous ischemia-reperfusion injury. Wound Repair Regen 19:505–514. https://doi.org/10.1111/j.1524-475X.2011.00704.x CrossRefPubMed

44.

Chevalier F, Arnaud D, Henault E et al (2015) A fine structural modification of glycosaminoglycans is correlated with the progression of muscle regeneration after ischaemia: towards a matrix-based therapy? Eur Cells Mater 30:51–68CrossRef

45.

Rouet V, Hamma-Kourbali Y, Petit E et al (2005) A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. J Biol Chem 280:32792–32800. https://doi.org/10.1074/jbc.M504492200 CrossRefPubMed

46.

Dragneva G, Korpisalo P, Yla-Herttuala S (2013) Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success. Dis Model Mech 6:312–322. https://doi.org/10.1242/dmm.010413 CrossRefPubMedPubMedCentral

47.

American Diabetes A (2003) Peripheral arterial disease in people with diabetes. Diabetes Care 26:3333–3341CrossRef

48.

Huysman E, Mathieu C (2009) Diabetes and peripheral vascular disease. Acta Chir Belg 109:587–594CrossRefPubMed

49.

Komi-Kuramochi A, Kawano M, Oda Y et al (2005) Expression of fibroblast growth factors and their receptors during full-thickness skin wound healing in young and aged mice. J Endocrinol 186:273–289. https://doi.org/10.1677/joe.1.06055 CrossRefPubMed

Title: Improved recovery from limb ischaemia by delivery of an affinity-isolated heparan sulphate
Authors: Selina Poon
Xiaohua Lu
Raymond A. A. Smith
Pei Ho
Kishore Bhakoo
Victor Nurcombe
Simon M. Cool
Publication date: 01-11-2018
Publisher: Springer Netherlands
Published in: Angiogenesis / Issue 4/2018
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-018-9622-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Improved recovery from limb ischaemia by delivery of an affinity-isolated heparan sulphate

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

A xenograft model for venous malformation

miR-153 inhibits the migration and the tube formation of endothelial cells by blocking the paracrine of angiopoietin 1 in breast cancer cells

IGF2 and IGF1R identified as novel tip cell genes in primary microvascular endothelial cell monolayers

Endothelial loss of Fzd5 stimulates PKC/Ets1-mediated transcription of Angpt2 and Flt1

Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy

eNOS expression and NO release during hypoxia is inhibited by miR-200b in human endothelial cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page